FDA Approves Fintepla Use in Broader Patient Population

March 28, 2022

UCB’s Fintepla® (fenfluramine) has obtained an expanded indication to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients at least two years of age.

  • When first FDA approved in 2020, Fintepla was indicated only to treat seizures associated with Dravet Both Dravet syndrome and Lennox-Gastaut syndrome are rare conditions that cause severe, drug-resistant epilepsy.
  • Recommended Fintepla dosing is based on the patient’s diagnosis, weight, and renal health; treatment efficacy and tolerability; and whether the patient is taking stiripentol and clobazam.
demo-attachment-261-Group-56
demo-attachment-606-Group-43
demo-attachment-1121-Rectangle-602

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager
demo-attachment-180-Group-4